# OnCo record idea-cns-first-adc-strategy (idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/ideas/idea-cns-first-adc-strategy/>
  a schema:CreativeWork ;
  onco:kind "idea" ;
  schema:identifier "idea-cns-first-adc-strategy" ;
  schema:name "Systemic-first management of HER2-positive brain metastases"@en ;
  schema:description "With Enhertu and tucatinib controlling brain metastases in most patients, radiation could be reserved for those who do not respond, sparing cognitive side effects."@en ;
  schema:url <https://onco.cc/ideas/idea-cns-first-adc-strategy/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT04739761>, <https://clinicaltrials.gov/study/NCT02614794> ;
  onco:cancers <https://onco.cc/cancers/breast-her2-positive/> ;
  onco:technologies <https://onco.cc/technologies/sbrt/> ;
  onco:drugs <https://onco.cc/drugs/trastuzumab-deruxtecan/>, <https://onco.cc/drugs/tucatinib/> ;
  onco:terms <https://onco.cc/terms/her2-brain-metastases/> ;
  onco:trials <https://onco.cc/trials/destiny-breast12/>, <https://onco.cc/trials/her2climb/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-trastuzumab-deruxtecan-breast-her2-positive-n-engl-j-med-2020/>, <https://onco.cc/key-papers/paper-her2climb-brain-lin-jco-2020/>, <https://onco.cc/key-papers/paper-tuxedo-1-trastuzumab-deruxtecan-brain-metastases-nat-med-2022/> .